# A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

Source: https://onco.cc/trials/nct06077877/  
OnCo record `nct06077877` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Niraparib in advanced solid tumours, run by GlaxoSmithKline, active and no longer recruiting.

## Summary

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors is a phase 1/2 interventional study registered as NCT06077877 by GlaxoSmithKline, with 42 participants enrolled, started 2023-10-24 and due to reach its primary completion in 2026-06-30. Interventions recorded: GSK4524101 and Niraparib.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06077877
- Phase: 1/2
- Setting: A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Polymerase Theta Inhibitor (POLQi) GSK4524101 and the PARP Inhibitor (PARPi) Niraparib in Adult Participants With Solid Tumors
- Sponsor: GlaxoSmithKline
- Enrolled: 42

## Sources

- ClinicalTrials.gov NCT06077877: https://clinicaltrials.gov/study/NCT06077877

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Niraparib](https://onco.cc/drugs/niraparib/)
- companies: [GSK](https://onco.cc/companies/gsk/)

---
JSON: https://onco.cc/api/v1/entities/nct06077877.json